Effects of pravastatin and rosuvastatin on the generation of adiponectin in the visceral adipose tissue in patients with coronary artery disease

Fundamental and Clinical Pharmacology

Volumn 25, Issue 3, 2011, Pages 378-387

  Yokoyama, Hiroaki ^a   Saito, Shin ^a   Daitoku, Kazuyuki ^a   Fukuda, Ikuo ^a   Higuma, Takumi ^a   Hanada, Hiroyuki ^a   Osanai, Tomohiro ^a   Okumura, Ken ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Adiponectin; Coronary artery disease; Oxidative stress; Statin; Visceral adipose tissue

Indexed keywords

ADIPONECTIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; DRUG EFFECT; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INTRAABDOMINAL FAT; MALE; PRIORITY JOURNAL; PROTEIN CARBONYLATION; SUBCUTANEOUS TISSUE; VALVULAR HEART DISEASE;

ADIPONECTIN; AGED; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; FEMALE; FLUOROBENZENES; HEART VALVE DISEASES; HUMANS; INTERLEUKIN-6; INTRA-ABDOMINAL FAT; MALE; MIDDLE AGED; OXIDATIVE STRESS; PRAVASTATIN; PROTEIN CARBONYLATION; PYRIMIDINES; SUBCUTANEOUS FAT; SULFONAMIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79954574112     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2010.00847.x     Document Type: Article

References (24)

1. Kumada M., Kihara S., Sumitsuji S. et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler. Thromb. Vasc. Biol. (2003) 23 85-89.
2. Ouchi N., Kihara S., Arita Y. et al. Novel modulator for endothelial adhesion molecules. Circulation (1999) 100 2473-2476.
3. Van Gaal L.F., Mertens I.L., De Block C.E. Mechanisms linking obesity with cardiovascular disease. Nature (2006) 444 875-880.
4. Eiras S., Teijeira-Fernandez E., Shamagian L.G., Fernandez A.L., Vazquez-Boquete A., Gonzalez-Juanatey J.R. Extension of coronary artery disease is associated with increased IL-6 and decreased adiponectin gene expression in epicardial adipose tissue. Cytokine (2008) 43 174-180.
5. Hattori S., Hattori Y., Kasai K. Hypoadiponectinemia is caused by chronic blockade of nitric oxide synthesis in rats. Metabolism (2005) 54 482-487.
6. Furukawa S., Fujita T., Shimabukuro M. et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. (2004) 114 1752-1761.
7. Kobayashi H., Ouchi N., Kihara S. et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ. Res. (2004) 94 27-31.
8. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation (2004) 109 39-43.
9. Saito S., Fujiwara T., Matsunaga T. et al. Increased adiponectin synthesis in the visceral adipose tissue in men with coronary artery disease treated with pravastatin: a role of the attenuation of oxidative stress. Atherosclerosis (2008) 199 378-383.
10. Hata Y., Mabuchi H., Saito Y. et al. Report of the Japan Atherosclerosis Society (JAS) guideline for diagnosis and treatment of hyperlipidemia in Japanese adults. J. Atheroscler. Thromb. (2002) 9 1-27.
11. Prevention of diabetes mellitus. Report of WHO Study Group. World Health Organ. Tech. Rep. Ser. (1994) 844 1-100.
12. Nakamura Y., Shimada K., Fukuda D. et al. Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart (2004) 90 528-533.
13. Yamamoto Y., Hirose H., Saito I. et al. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin. Sci. (2002) 103 137-142.
14. Iwashima Y., Katsuya T., Ishikawa K. et al. Association of hypoadiponectinemia with smoking habit in men. Hypertension (2005) 45 1094-1100.
15. Miyazaki T., Shimada K., Mokuno H., Daida H. Adipocyte derived plasma protein, adiponectin, is associated with smoking status in patients with coronary artery disease. Heart (2003) 89 663-664.
16. Takebayashi K., Suetsugu M., Matsumoto S., Aso Y., Inukai T. Effects of rosuvastatin and colestimide on metabolic parameters and urinary monocyte chemoattractant protein-1 in type 2 diabetic patients with hyperlipidemia. South. Med. J. (2009) 102 361-368.
17. Inoue T., Kotooka N., Morooka T. et al. High molecular weight adiponectin as a predictor of long-term clinical outcome in patients with coronary artery disease. Am. J. Cardiol. (2007) 100 569-574.
18. Iacobellis G., Pistilli D., Gucciardo M. et al. Adiponectin expression in human epicardial adipose tissue in vivo is lower in patients with coronary artery disease. Cytokine (2005) 29 251-255.
19. McTaggart F. Comparative pharmacology of rosuvastatin. Atheroscler Suppl. (2003) 4 9-14.
20. Soares A.F., Guichardant M., Cozzone D. et al. Effects of oxidative stress on adiponectin secretion and lactate production in 3T3-L1 adipocytes. Free Radic. Biol. Med. (2005) 38 882-889.
21. Okamoto Y., Higashiyama H., Rong J.X. et al. Comparison of mitochondrial and macrophage content between subcutaneous and visceral fat in db/db mice. Exp. Mol. Pathol. (2007) 83 73-83.
22. Maeda N., Takahashi M., Funahashi T. et al. PPAR γ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes (2001) 50 2094-2099.
23. Fasshauer M., Kralisch S., Klier M. et al. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. (2003) 301 1045-1050.
24. Bruun J.M., Lihn A.S., Verdich C. et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am. J. Physiol. Endocrinol. Metab. (2003) 285 527-533.